Department of Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan, China.
J Ovarian Res. 2022 May 2;15(1):51. doi: 10.1186/s13048-022-00985-3.
There have been a variety of published studies on the expression of serum miR-21 in patients with ovarian cancer associated with the diagnostic value of ovarian cancer, but the conclusions are not clearly elucidated. This study aims to evaluate the value of serum miR-21 expression in the diagnosis of patients with ovarian cancer by meta-analysis.
Databases, such as PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China WanFang, were searched for relevant studies upon the correlation between the expression of serum miR-21 and the diagnostic value of ovarian cancer from inception to March 7, 2022. Statistical analysis was performed using Stata 15.0 software. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated. The meta-regression analysis and subgroup analysis were used to explore the sources of heterogeneity. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) system was used to evaluate the quality of the included literature.
A total of 6 articles were included in the meta-analysis. The results showed that the pooled sensitivity, specificity, PLR, NLR, and DOR were 0.81 (95%CI: 0.73-0.88), 0.82 (95%CI: 0.75-0.87), 4.51 (95%CI: 3.22-6.31), 0.23 (95%CI: 0.16-0.33), and 19.87 (95% CI: 11.27-35.03), respectively. The area under the summary receiver operating characteristic curve was 0.89 (95%CI: 0.85-0.91). No significant publication bias was found (P > 0.05).
Serum miR-21 has a good diagnostic value for ovarian cancer, which can be an ideal diagnostic biomarker for ovarian cancer. However, we should gingerly use miR-21 as a diagnostic reference standard, due to the limited number of included studies and heterogeneity.
已有多种关于血清 miR-21 在卵巢癌患者中表达的研究，这些研究与卵巢癌的诊断价值相关，但结论并不明确。本研究旨在通过荟萃分析评估血清 miR-21 表达在卵巢癌诊断中的价值。
检索 PubMed、Embase、Web of Science、Cochrane Library、中国知网（CNKI）和万方数据库，搜集 miR-21 表达与卵巢癌诊断价值相关的研究，检索时限均从建库至 2022 年 3 月 7 日。采用 Stata 15.0 软件进行统计学分析。计算合并敏感度、特异度、诊断比值比（DOR）、阳性似然比（PLR）、阴性似然比（NLR）。采用亚组分析和 Meta 回归分析探索异质性来源。采用诊断准确性研究质量评价工具 2（QUADAS-2）系统评价纳入文献的质量。
共纳入 6 篇文献进行荟萃分析。结果显示，血清 miR-21 检测诊断卵巢癌的合并敏感度、特异度、PLR、NLR、DOR 分别为 0.81（95%CI：0.730.88）、0.82（95%CI：0.750.87）、4.51（95%CI：3.226.31）、0.23（95%CI：0.160.33）、19.87（95%CI：11.2735.03），汇总受试者工作特征曲线下面积为 0.89（95%CI：0.850.91）。未发现明显发表偏倚（P>0.05）。
血清 miR-21 对卵巢癌具有较好的诊断价值，可作为卵巢癌理想的诊断标志物。但由于纳入研究数量有限，且存在异质性，应谨慎将 miR-21 作为诊断参考标准。
